Global Hemoglobin A1C Testing Devices Market Report 2023: Rising Prevalence of Diabetes Fuels the Sector

The “Hemoglobin A1c Testing Devices Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global hemoglobin A1c testing devices market is expected to grow from $1.54 billion in 2022 to $1.72 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The hemoglobin A1c testing devices market is expected to reach $2.56 billion in 2027 at a CAGR of 10.3%.

Major players in the hemoglobin a1c testing devices market are Arkray Inc., Abbott Laboratories, Polymer Technology Systems Inc., Bio-Rad Laboratories Inc., Menarini Group, F Hoffmann-La Roche AG, Semba Biosciences Inc., Siemens Healthineers AG, Tosoh Corporation, Trinity Biotech plc, Transasia Bio-Medicals Limited, Beckman Coulter Inc., Diazyme Laboratories Inc., EKF Diagnostics Holdings plc, HemoCue AB, and OSANG Healthcare Co Ltd.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the RussiaUkraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis


The hemoglobin A1c testing device is the analytical device used in the quantification of HbA1C, in which glucose attaches to hemoglobin to form glycated hemoglobin in an individual blood sample. It is used to monitor blood sugar levels regularly for efficient and effective diabetic management.

The main types of hemoglobin a1c testing devices are bench top device and handheld device. Benchtop devices are devices for convenient use on a laboratory workbench. Benchtop hemoglobin A1c testing devices are used in laboratories for testing blood sugar levels in a patients. The major technologies are ion exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others, that are used in hospitals, pharmaceuticals, medical devices, and laboratory testing.

Product innovations are a key trend in gaining popularity in the hemoglobin A1c testing devices market. Major companies operating in the market are focused on developing innovative products to strengthen their position in the market. 

North America was the largest region in the hemoglobin A1c testing devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobin A1c testing device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hemoglobin A1c testing device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The rising prevalence of diabetes is expected to propel the growth of the hemoglobin A1c testing devices market. Diabetes is a chronic metabolic disorder that elevates blood glucose levels. Hemoglobin A1c testing is used in providing information on average blood glucose levels in individuals that are used in the diagnosis of type 2 diabetes, pre-diabetes, and diabetes management, which enables the individuals to monitor the disease and help make treatment decisions to prevent complications.

For instance, in 2022, Centers for Disease Control and Prevention, a US-based national public health agency, around 37.3 million people were suffering from diabetes which equals 11.3% of the United States population. Additionally, in December 2021, according to the International Diabetes Federation, a Belgium-based global diabetes community, approximately 537 million adults were suffering from diabetes globally, whereas 3 out of 4 adults are in low- and middle-income countries. Therefore, the increased cases of diabetes patients will drive the hemoglobin A1c testing devices market.

The hemoglobin A1c testing device market consists of sales of automated, semi-automated, and bio-sensor-based hemoglobin A1c testing devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Key Topics Covered:

1. Executive Summary

2. Hemoglobin A1c Testing Devices Market Characteristics

3. Hemoglobin A1c Testing Devices Market Trends And Strategies

4. Hemoglobin A1c Testing Devices Market – Macro Economic Scenario
4.1. COVID-19 Impact On Hemoglobin A1c Testing Devices Market
4.2. Ukraine-Russia War Impact On Hemoglobin A1c Testing Devices Market
4.3. Impact Of High Inflation On Hemoglobin A1c Testing Devices Market

5. Hemoglobin A1c Testing Devices Market Size And Growth
5.1. Global Hemoglobin A1c Testing Devices Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Hemoglobin A1c Testing Devices Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Hemoglobin A1c Testing Devices Market Segmentation
6.1. Global Hemoglobin A1c Testing Devices Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Bench Top Device
  • Handheld Device

6.2. Global Hemoglobin A1c Testing Devices Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Ion-Exchange HPLC
  • Immunoassay
  • Boronate Affinity Chromatography
  • Direct Enzymatic Assay
  • Other Technologies

6.3. Global Hemoglobin A1c Testing Devices Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Hospitals
  • Pharmaceuticals
  • Medical Devices
  • Laboratory Testing

7. Hemoglobin A1c Testing Devices Market Regional And Country Analysis
7.1. Global Hemoglobin A1c Testing Devices Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Hemoglobin A1c Testing Devices Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/hc6gyh

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version